[Asia Economy Reporter Lee Jung-yoon] Genexine announced on the 26th that it has decided to conduct a paid-in capital increase through a rights offering followed by a general public offering of forfeited shares, amounting to 100 billion KRW, to raise operating funds.
The new shares consist of 5,797,102 common shares, with an issue price of 17,250 KRW per share.
Additionally, Genexine has also decided on a bonus issue, allocating 0.3 shares for every 1 common share held.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
